Evidence map›Paper›PMID 40957899›Full record

Trial reportInternational journal of obesity (2005)2026

Quality of life improvements associated with weight loss using a novel shape-shifting hydrogel capsule: RESET study results.

Robert F Kushner, Jamy D Ard, Thomas A Wadden, Patrick M O'Neil, Harold E Bays, Frank L Greenway, John M Jakicic, Holly R Wyatt, Yael Kenan, Liora Cohen Asaraf and 1 more

Erratum issuedAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in International journal of obesity (2005), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Robert F KushnerDepartment of Medicine, Division of Endocrinology, Metabolism, and Molecular Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. rkushner@northwestern.edu.ORCID 0000-0002-1380-3705
Jamy D ArdDepartment of Epidemiology and Prevention and Department of Medicine, Wake Forest University School of Medicine, Winston, Salem, NC, USA.ORCID 0000-0002-1643-6795
Thomas A WaddenDepartment of Psychiatry, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.ORCID 0000-0002-0438-4609
Patrick M O'NeilWeight Management Center, Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, SC, USA.
Harold E BaysLouisville Metabolic and Atherosclerosis Research Center, Louisville, KY, USA.
Frank L GreenwayPennington Biomedical Research Center, Louisiana State University, Baton Rouge, LA, USA.ORCID 0000-0002-1766-6111
John M JakicicDivision of Physical Activity and Weight Management, Department of Internal Medicine, University of Kansas Medical Center, Kansas City, KS, USA.ORCID 0000-0001-6800-9368
Holly R WyattDepartment of Nutrition Sciences, The University of Alabama at Birmingham, Birmingham, AL, USA.
Yael KenanEpitomee Medical Ltd, Caesarea, Israel.
Liora Cohen AsarafEpitomee Medical Ltd, Caesarea, Israel.
Donna H RyanPennington Biomedical Research Center, Louisiana State University, Baton Rouge, LA, USA.

Funding

Why is the prevalence of obesity so high in U.S. Southern States? Regional predictors of BMI and obesity treatment response.P30DK056336 · NIDDK · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI James O Hill · 2000 to 2026
$31.9M
NIDDK NIH HHS P30 DK056336
6 · The paper itself

Abstract

objectiveTo evaluate the impact of the Epitomee capsule on quality of life (QOL) and its association with weight loss in adults with overweight and obesity.

methodsThis study analyzed the RESET double-blind, placebo-controlled results, focusing on predefined QOL endpoints and post hoc analyses. A total of 279 participants with a BMI of 27-40 kg/m² were treated for 24 weeks with Epitomee or placebo, along with lifestyle intervention. Statistical analyses examined changes in IWQOL-Lite-CT scores, their relationship with weight loss, and subgroup differences.

resultsCompared to the placebo group, the Epitomee group consistently showed improved outcomes in total IWQOL-Lite-CT score and Physical Function sub-score (p < 0.05), as well as numerically higher improvements in the Physical and Psychosocial sub-scores, although these did not reach statistical significance. Both treatment groups showed a significant improvement (p < 0.05) from baseline in the IWQOL-Lite-CT total score, as well as in Physical, Physical Function, and Psychosocial sub-scores over the 24-week period. A stronger correlation between weight loss and QOL improvements was observed with Epitomee vs. placebo.

conclusionsThe Epitomee capsule, with lifestyle intervention, is associated with IWQOL-Lite-CT improvement, highlighting its potential as an effective non-pharmaceutical adjunct to lifestyle intervention for enhancing health outcomes in individuals with overweight and obesity.

Indexed as

HydrogelsObesityOverweightQuality of LifeWeight LossAdultCapsulesDouble-Blind MethodFemaleHumansMaleMiddle AgedTreatment OutcomeCapsulesHydrogels

Identifiers

PMID40957899
PMCPMC12855005

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.